MultiHance for MR Angiography approved in Europe

Bracco Imaging announces that the MR Angiography indication for MultiHance has been approved by the EU member states via a mutual recognition procedure. MultiHance is a gadolinium based contrast agent that is characterized by high relaxivity and dual route of excretion.

Photo: MultiHance for MR Angiography approved in Europe
The new MRA licence widens the range of applications for MultiHance, which alreadz included the MRI of the liver for the detection of focal liver lesions in adult patients with known or suspected primary liver cancer or metastatic disease, an the MRI of the brain and spine where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI.
MulitHance is indicated for Contrast-enhanced MR-angiography with a focus of detecting clinically significant steno/occlusive vascular disease in adult patients with suspected or known vascular disease of the abdominal or peripheral arteries.


Read all latest stories

Related articles


Article • CEUS

Advancing contrast enhanced ultrasound

The ability to demonstrate blood perfusion as well as organ function using contrast agentenhanced ultrasound is quickly finding innovative uses in clinical practice. Contrast-enhanced ultrasound…


Article • Gadolinium-based contrast agents

Clinicians define optimal approach for MRI contrast to maximize benefit

Gadolinium-based contrast agents are an essential component of MRI exams, but are challenged by findings of residual depositions of gadolinium in the body, even though the clinical relevance remains…


Article • Contrast enhancement

Sonic boom with bubbles

Illuminating blood vessels, opening the blood-brain barrier and delivering drugs. What will be the next big thing that tiny microbubbles can do?

Related products

Subscribe to Newsletter